Cancer Gene Therapy Market to Grow with a CAGR of 20.12% through 2030
The growing prevalence of cancer is expected to drive the
growth of global cancer gene therapy in the forecast period, 2026-2030.
According to TechSci Research report, “Cancer Gene
Therapy Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2030F”, Global Cancer Gene Therapy Market was valued at USD
4.52 billion in 2024 and is expected to reach USD 13.58 billion by 2030 with a
CAGR of 20.12% during the forecast period. This can be ascribed to the
growing approvals of gene therapy products for the treatment of different types
of cancer across the globe. Additionally, growing advancements in gene therapy,
growing research, and developments of gene therapies will further enhance the
demand for advanced cancer gene therapy during the forecast period. Similarly,
growing demand for minimally invasive procedures for the treatment of cancer
especially in the developed countries in North America and Europe is expected
to create lucrative opportunities for market growth in coming years. Besides,
growing awareness among patients and healthcare providers about new cancer gene
therapy will boost the market growth over the years. Also, favorable government
reimbursement policies for the treatment and diagnosis of cancer are expected
to create lucrative growth in the market during the forecast period. The
improvement of rules and regulations to create a more reasonable supervisory
mechanism along with the development of biotechnology research, applications
and related business will further boost the market growth during the forecast
period.
However, high cost of gene therapy can create affordability
issues thereby slowing down the growth of Global Cancer Gene Therapy Market in
the forecast period. Similarly, high risks and complications associated with
treatments and unwanted immune responses may hamper The Cancer Gene Therapy
Market growth during the forecast period. Also, lack of awareness about new
gene therapy for the treatment and poor reimbursement scenario with lack of
insurance coverage in emerging countries can further restrict the growth of
Global Cancer Gene Therapy Market. Also, lack of skilled healthcare workers for
handling the management scenario in the healthcare sector can restrain the
growth of the market over the years.
The global cancer gene therapy market is
segmented into therapy, indication, end user, regional distribution and
company.
Based on Indication, Lung Cancer is currently showing the
fastest growth in the global cancer gene therapy market. This surge is driven
by the high global incidence and mortality rates associated with lung cancer,
particularly non-small cell lung cancer (NSCLC), which constitutes most lung
cancer cases. According to the World Health Organization (WHO), lung cancer
remains the leading cause of cancer-related deaths worldwide, accounting for
approximately 1.8 million deaths annually. This significant burden is
compelling researchers and pharmaceutical companies to develop more effective
and targeted therapies, including gene therapies. Gene therapy
advancements in lung cancer have primarily focused on targeting mutations in
EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), and
KRAS—genetic alterations commonly associated with resistance to traditional
chemotherapy. Recent innovations, such as CRISPR-Cas9 gene editing and
RNA-based therapies, are being explored for their ability to directly target
these mutations and modulate immune responses. Additionally, the growing use of
liquid biopsies and next-generation sequencing (NGS) to detect actionable
mutations early has facilitated more precise, gene-targeted approaches for lung
cancer. Governments and health systems in countries such as the U.S., China,
and Japan are also supporting early diagnosis and genomic research,
accelerating the adoption of gene-based therapies in lung oncology.
Based on the Region, Asia Pacific is witnessing the fastest
growth in the global cancer gene therapy market, driven by a combination of
rising cancer incidence, increasing healthcare investments, and expanding
biotechnology capabilities across countries such as China, India, Japan, and
South Korea. The region is experiencing a demographic shift marked by a growing
aging population, which contributes to a higher cancer burden, thereby
necessitating more advanced and personalized treatment options such as gene
therapy. Governments across the Asia Pacific are actively supporting
genomics and gene therapy development through national healthcare initiatives
and research funding. For example, China’s "Healthy China 2030" plan
emphasizes the integration of precision medicine and gene-based diagnostics and
treatments into the national healthcare system. Additionally, India's
Department of Biotechnology and Japan’s AMED (Japan Agency for Medical Research
and Development) are fostering innovation through public-private collaborations
in cancer research. Rapid technological advancements and lower manufacturing
costs in the region have encouraged both local and international pharmaceutical
companies to establish R&D and manufacturing facilities in Asia Pacific.
The growing participation of patients in clinical trials, along with improving
regulatory pathways in countries like South Korea and Singapore, also
contributes to accelerated development and access to cancer gene therapies.
With increased awareness, improved access to diagnostics, and a focus on
expanding oncology care, Asia Pacific is positioned to become a major growth
engine for the cancer gene therapy market in the coming years.
Major companies operating in the Global Cancer Gene
Therapy market are:
- Abeona
Therapeutics Inc.
- Asklepios
BioPharmaceutical Inc.
- Altor
Bioscience Inc.
- BioCancell
Inc.
- Celgene
Inc.
- Elevate
Bio Inc.
- Genelux
Corporation
- Introgen
Therapeutics Inc.
- OncoGenex
Pharmaceuticals Inc.
- Merck
KGaA
Download Free Sample Report
Customers can also request for 10% free customization
on this report.
“The North America was expected to dominate in the
Global Cancer Gene Therapy Market on account due to the increasing
number of major key players in the market and rising collaboration with other
companies across the region. Furthermore, increasing research and developing
activities along with growing awareness about new therapies are further
contributing to demand for cancer gene therapy. Besides, the availability of
skilled professionals and early adoption of advanced treatments of different
types of cancer like breast cancer, prostate cancer, and blood cancer and
growing demand for DNA vaccines, growing improvement of regulatory standards
regarding the quality of the products used in gene therapy across the
developing region is further expected to create lucrative opportunities for the
market growth”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based global management consulting firm.
“Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer, and Others), By Indication (Breast Cancer, Ovarian Cancer, Lung Cancer, Liver Cancer, Pancreatic Cancer, Prostate Cancer, and Others), By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, and Others), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of
global cancer gene therapy market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in global cancer gene therapy market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com